



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006, OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |      |                          |                   |
|---|------|--------------------------|-------------------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |      | <b>Complete if Known</b> |                   |
|   |      | Application Number       | 10/706,241        |
|   |      | Filing Date              | November 12, 2003 |
|   |      | First Named Inventor     | KERSHMAN, Alvin   |
|   |      | Art Unit                 | Not Yet Assigned  |
|   |      | Examiner Name            | Not Yet Assigned  |
| Sheet 1   | of 1 | Attorney Docket Number   | 45100-8802301     |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| J                               | 1                     | PETER J. SNYDER, Androgens, The Pharmacological Basics of Therapeutics, 10th ed., pages 1635-1648, Goodman and Gilman   |                |
|                                 | 2                     | SVEND G. JOHNSEN, EDGAR P. BENNETT, V. GUANO JENSEN, Therapeutic Effectiveness of Oral Testosterone, The Lancet, December 21, 1974, pages 1473-1475.  |                |
|                                 | 3                     | MARIE FOGH, CHARLES S. CORKER, HELEN McLEAN, IVAN BRUUNSHUUS PETERSEN, JOHN PHILIP AND NIELS E. SKAKKEBAK, Serum-Testosterone During Oral Administration of Testosterone in Hypogonadal Men and Transsexual Women, ACTE Endocrinologica, 1978, pages 643-649    |                |
|                                 | 4                     | P.R. DAGGETT, M.J. WHEELER AND J.D.N. NABARRO, Oral Testosterone, a Reappraisal, 1978, pages 121-129  |                |
|                                 | 5                     | E. NIESCHLAG, H.J. CUPPERS & E.J. WICKINGS, Influence of sex, testicular development and liver function on the bioavailability of oral testosterone, European Journal of Clinical Investigation, 1977, pages 145-147.   |                |
|                                 | 6                     | H. FREY, A. AAKVAAG, D. SAANUM AND J. FALCH, Bioavailability of Oral Testosterone in Males, European Journal of Clinical Pharmacology, 1979, pages 345-349  |                |
|                                 |                       |   |                |
|                                 |                       |   |                |

|                    |  |                 |      |
|--------------------|--|-----------------|------|
| Examiner Signature |  | Date Considered | 6/07 |
|--------------------|--|-----------------|------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.